Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Aug 16, 2019
Date Accepted: Feb 7, 2020

The final, peer-reviewed published version of this preprint can be found here:

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach

Ector G, Westerweel P, Hermens R, Braspenning K, Heeren B, Vinck O, de Jong J, Janssen J, Blijlevens N

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach

J Med Internet Res 2020;22(5):e15895

DOI: 10.2196/15895

PMID: 32412424

PMCID: 7260663

The Development of a Web-based Patient-centered Intervention for Patients with Chronic Myeloid Leukemia: CMyLife.

  • Geneviève Ector; 
  • Peter Westerweel; 
  • Rosella Hermens; 
  • Karin Braspenning; 
  • Barend Heeren; 
  • Oscar Vinck; 
  • Jan de Jong; 
  • Jeroen Janssen; 
  • Nicole Blijlevens

ABSTRACT

Background:

With a global rise in chronic conditions health care is transforming and patient empowerment is emphasized, in order to improve treatment outcomes and reduce healthcare costs. Patient-centered innovations are needed and can be developed using design thinking, a valued methodology in IT and business, though little used in healthcare.

Objective:

The aim of this article was to develop a patient-centered innovation using the design thinking methodology. We focused on patients with chronic myeloid leukemia (CML), a chronic disease with a generally good long-term prognosis due to the advent of tyrosine kinase inhibitors. Adherence by both patients and physicians is suboptimal, unnecessarily jeopardizing treatment outcomes.

Methods:

The five phases of design thinking (empathize, define, ideate, prototype and test) were went through and all started with the patient. Stakeholders and end-users were identified and interviewed and observations in the care system were made. Using tools in human-centered design, problems were defined an various solution prototypes were generated. These were evaluated by patients and stake-holders and then further refined.

Results:

Patients desired: 1. insights in their own disease and 2. insights in experienced symptoms, both in terms of knowledge and comprehension, 3. improvement of logistics of care delivery. A web-based platform was developed and ran as a pilot: CMyLife. It has multiple features, all parts of the bigger solution, including: a website with reliable information and forum, guideline app, personal medical record with logs of symptoms and lab results (including molecular marker and linked to the guideline app), screen-to-screen consulting, delivery of medication and collecting blood samples at home.

Conclusions:

Design thinking resulted in the multidisciplinary development of the patient-centered innovation CMyLife. Possibly it could increase empowerment, both patient and physician adherence, quality of life and result in a digital centralization of care. Whether CMyLife achieves these goals needs to be evaluated in future studies. Clinical Trial: N/A


 Citation

Please cite as:

Ector G, Westerweel P, Hermens R, Braspenning K, Heeren B, Vinck O, de Jong J, Janssen J, Blijlevens N

The Development of a Web-Based, Patient-Centered Intervention for Patients With Chronic Myeloid Leukemia (CMyLife): Design Thinking Development Approach

J Med Internet Res 2020;22(5):e15895

DOI: 10.2196/15895

PMID: 32412424

PMCID: 7260663

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.